In South Korea, bioequivalence requirements for generic drugs involve demonstrating that the generic product has similar bioavailability to the reference drug. This is achieved through clinical studies comparing the rate and extent of absorption. The Ministry of Food and Drug Safety (MFDS) evaluates these studies to ensure therapeutic equivalence and approval for market entry.